TuHURA Biosciences reports Q3 results, initiates Phase 3 trial for Merkel cell carcinoma.

• TuHURA Biosciences starts Phase 3 trial for IFx-2.0 in MCC • Trial is adjunctive therapy with Keytruda for first-line therapy • FDA granted Special Protocol Assessment (SPA) agreement • DOR technology selected for oral presentation at ASH Annual Meeting • 2 poster presentations at ASH Annual Meeting • TuHURA reports Q3 financial results and provides corporate update • Focus on clinical development program execution • Enrolling patients in ongoing trials